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Abstract
Introduction and hypothesis In order to better understand
provider treatment patterns for interstitial cystitis (IC)/painful
bladder syndrome, we sought to document the therapies
utilized and their associated expenditures using a national
dataset.
Methods A cohort was created by applying the ICD-9
diagnosis of IC (595.1) to INGENIX claims for the year
1999. Subjects were followed for 5 years, and patterns of
care and related expenditures were evaluated.
Results Of 553,910 adults insured in 1999, 89 subjects had a
diagnosis of IC with 5-year follow-up data. All subjects were
treated with oral medication(s), 26% received intravesical
treatments, and 22% underwent hydrodistension. Total
expenditures per subject were $2,808.
Conclusions The majority of IC expenditures were attribut-
able to oral medical therapy. Hydrodistension and intravesical
instillations were utilized in less than 25% of patients.
Hydrodistension was used more frequently among subjects
withanewdiagnosis;thismayreflectitsutilizationaspartofa
diagnostic algorithm.
Keywords Interstitial cystitis.Treatment.Bladder pain.
Cost.Claims data.Ingenix
Introduction
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a
debilitating disease that presents with a constellation of
symptoms including pelvic pain, urinary urgency, frequency,
nocturia, and small voided volumes in the absence of other
identifiable etiologies. Reports of its prevalence vary; it is
reported to affect 10/100,000 of the population in Finland[1].
In 1989 it was estimated to affect 501/100,000 individuals
(0.5%) in the US [2]. Studies have shown that this disease
significantly impacts quality of life; patients with IC/PBS
score lower than women without IC/PBS in four out of
seven dimensions measured by the short-form health
survey (SF-36) questionnaire including physical function,
vitality, social function, and bodily pain domains [3]. A
study in a population of managed care patients in the US
demonstrated that this disease is underreported; the
prevalence may be 30–50-fold higher in women and 60–
100-fold higher in men[4].
The economic burden of IC/PBS is significant. Incremental
medicalcosts areestimated to exceed$100million per year [5]
and total income lost to IC in 1987 was estimated to be from
$177 to $311 million [6]. In a study by the Urologic Diseases
in America Project, the average total annual medical cost per
person with an IC/PBS diagnosis was $7,597; more than
double the figure for those without the diagnosis, after
controlling for several factors [7]. A study of a managed care
population found costs associated with IC/PBS to be $4,000
greater than for age-matched controls [8]. A multimodal
treatment approach is usually employed in treating these
patients. The goal of this study is to better understand
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Methods
This study was part of the Urologic Diseases in America
Project. Ingenix is a claims-based dataset, which captures
utilization of medical services for approximately 1.8 million
employees, retirees, and dependants of 25-large Fortune 500
employers [9]. The sample used consisted of primary
beneficiaries, age 18–64 years, who were continuously
enrolled for the year 1999. A cohort was created by applying
the ICD-9 diagnosis code for IC/PBS (595.1) to claims for
the year 1999. We did not exclude the diagnosis of
overactive bladder (OAB), partly because there is no ICD-
9 code specific for OAB other than 596.51 (hypertonicity of
bladder). Since many of the symptoms of OAB overlap with
IC codes, such as frequency/urgency/nocturia, and OAB is
not easily diagnosed with codes, we chose not to exclude
these patients. Although it is possible that there are cases that
were misdiagnosed, we suspect that this number is small.
This cohort was followed for 5 years in order to obtain long-
term data on these subjects. Claims for both prevalent and
incident cases were analyzed. Incident cases were identified
by excluding subjects with a claim for IC/PBS in 1998.
The medical claims in the Ingenix dataset include financial
information,diagnosis,and procedure codes,drugclaims,and
national drug codes which were used to examine utilization of
specific drugs. We identified oral medications and procedures
utilized as well as their duration of use and associated
expenditures; Appendix 1 identifies the medications queried
and Appendix 2 summarizes procedures and their associated
CPT-4 procedure codes.
Results
In the year 1999, a total of 553,910 individuals were covered.
A total of 321 women had IC/PBS in 1999, including both
incident and prevalent cases. Eighty-nine women had follow-
up data for 5 years; out of these, 54 subjects were incident
cases, i.e., they had no claims for IC/PBS in 1998 and had IC/
PBS claims in 1999. The mean and median age in the total
insured population in the dataset was 58.5 and 59 years,
respectively. The mean and median age among the cohort
with IC/PBS was 63.3 and 65 years, respectively, and that of
the incident cases was 63 and 64.5 years. The age distribution
of the cohort is shown in Table 1.
All patients had at least one claim for an oral medication
indicated for symptoms of IC/PBS. Medications used by
morethan10% ofthe subjectsinprevalentandincidentcases,
respectively, were PPS (35%, 15%), tolterodine (31%, 31%),
amitriptyline (25%, 13%), gabapentin (19%, 15%), and
oxybutinin (18%, 17%); the average duration of therapy for
all of these medications in all patients was 72 weeks. Among
medications used to treat IC/PBS, anticholinergics were the
most common class utilized (49% for tolterodine and
oxybutinin combined, Table 2). Narcotic pain medications
were utilized by 84% of the subjects (Table 3).
Twenty-two percent of all subjects and 30% of the incident
cases underwent hydrodistension; intravesical therapies were
used in treatment of 26% and 17% of all and incident cases,
respectively (Table 4). These therapies were not repeated
when used, with the exception of one patient who had a
repeat intravesical instillation. Additionally, when treated
with intravesical therapies, not all subjects received a full 6-
week course of treatment; treatments ranged from 2 to
6 weeks, with an average of 4.4 weeks.
Expenditures for all IC/PBS-specific treatments combined
for the cohort were $2,808 per patient over 5 years. This does
not include related expenditures for physician evaluation,
laboratory and/or radiology testing. Oral medical therapy
represented 82%, hydrodistension 15%, and intravesical
instillations 3% of the overall expenditures. Among the
medications used by more than 10% of the subjects, PPS
was the most costly at $36/week, followed by gabapentin at
$20/week, oxybutinin at $18/week, and tolterodine at $17/
week. The duration of utilization was the highest for PPS
(99.5 weeks), followed by gabapentin (87.4 weeks), oxy-
butinin (55.3 weeks) and tolterodine (48.5 weeks).
Discussion
This study has several important findings that shed light on
the patterns of care for adults with IC/PBS. First, we found
that all of the subjects were treated with at least one oral
Age (years) Number Percent (%) Cumulative frequency Cumulative percent (%)
21–30 3 3.37 3 3.37
31–40 4 4.49 7 7.87
41–50 11 12.36 18 20.22
51–65 29 32.58 47 52.81
>65 42 47.19 89 100.00
Table 1 Age distribution of
patients with IC in cohort
(prevalent and incident cases)
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study period. Of these, narcotics were the most commonly
utilized class of medications. This might indicate that many
commonly prescribed IC/PBS-specific medications are less
effective than narcotics. Alternatively, the narcotics may
have been used to treat other pain complaints arising from
sites other than the bladder. Anticholinergics were the
second most commonly utilized class of medications used
by 49% of subjects (tolterodine and oxybutinin combined)
with an average utilization period of approximately 1 year.
This utilization period is actually longer than that docu-
mented for women with overactive bladder symptoms
[10,11]. In the Interstitial Cystitis Data Base (ICDB) study,
a multicenter, observational study designed to document the
treatment history of IC/PBS and patient characteristics, only
2–4% of patients received anticholinergics as monotherapy
or in combination with other medications [12]. However,
this was a select cohort of patients who were recruited from
a limited number of tertiary care centers. Our data suggest
that anticholinergic agents are used much more widely in
the community setting. This observation reinforces the
inherent difficulty in distinguishing between the clinical
syndromes of overactive bladder and IC/PBS, since many of
symptoms overlap. It is possible that there is therapeutic
benefit gained from this group of medications by patients with
IC/PBS, or alternatively, they may have seen a slight benefit
with little side effects and are willing to continue these
medications since they were not offered other therapies.
A substantial minority of patients were treated with
centrally acting medications including gabapentin and tricy-
clic antidepressants. These medications have been used in
treatment of chronic pain conditions such as Complex
Regional Pain Syndrome Type-I (CPRS-I) with success. It
has been suggested that the pathophysiology of IC/PBS may
partly be due to deregulation of the central nervous system,
similartoCPRS-I[13]. Gabapentin, an antiepileptic, has been
effective in treatment of chronic sympathetically mediated
pain syndromes and there are reports of its efficacy in
treatment of IC/PBS [13][ 14]. Tricylic antidepressants such
as amitriptyline also have demonstrated efficacy in treating
patients with IC/PBS [15–17]. In our cohort, gabapentin and
amitriptyline were among the five most commonly used
medications and were used to treat 19% and 25% of patients,
respectively. This is slightly higher than the 17% of subjects
treated with amitriptyline in the ICDB study [15–17]. Given
the theory that the etiology of IC/PBS/chronic pelvic pain
may reside partly in the central nervous system, a shift
toward treatments aimed at regulating the nervous system is
logical. While claims data cannot be used to infer the reasons
for the low rate of utilization of centrally acting medications
in the Ingenix cohort, possible explanations include a lack of
provider awareness of the potential role of central nervous
Drug N treated Percentage treated (%) Duration (weeks) Total Cost
All cases Detrol 28 31 48.52 $23,265
Ditropan 16 18 55.30 $16,123
Neurontin 17 19 87.43 $30,332
Elmiron 31 35 99.55 $112,144
Elavil 22 25 67.86 $2,375
Incident cases Detrol 17 31 43.14 $11,478
Ditropan 9 17 64.49 $9,290
Neurontin 8 15 77.93 $13,660
Elmiron 8 15 81.61 $26,120
Elavil 7 13 32.63 $365
Table 2 Utilization and cost of
oral medication for IC
Table 3 Narcotic usage among patients with IC
IC in 1999
(N=89)
IC in 1999, no IC in 1998
(N=54)
IC in 1999 and 1998
(N=35)
Number of people who took any narcotic in 1999 40 22 18
Percentage of people who took any narcotic in 1999 (%) 45 41 51
Total number of scripts filled in 1999 90 40 50
Total day supply of narcotics in 1999 1,302 485 817
Number of people who took any narcotic 1999–2003 75 45 30
Percentage people took any narcotic 1999–2003 (%) 84 83 86
Total number of scripts filled 1999–2003 623 250 373
Total day supply of narcotics 1999–2003 11,197 4,731 6,466
Int Urogynecol J (2011) 22:395–400 397system dysregulation in this syndrome or low perceived
efficacy of available agents to mitigate this dysregulation.
Further prospective work in this area would be helpful to
further interpret this finding.
In our cohort, PPS was utilized by 35% of all subjects and
15% of the incident cases with a mean utilization period of
99.5 and 82 weeks, respectively. PPS is the only oral
medication approved by the Food and Drug Administration
(FDA) for the treatment of IC/PBS. One theory of the
pathophysiology of IC/PBS implicates a defect in the bladder
glycosaminoglycan layer as partially responsible for symp-
toms of IC/PBS. PPS, which is available in oral formulation
and is excreted in urine, is prescribed with the intent to correct
this defect [18]. The studies evaluating its efficacy have
shown a wide array of clinical responses. A multicenter
randomized controlled trial showed that 32% of those on
PPS compared to 16% of patients on placebo reported more
than 50% improvement in a global self-evaluation of their
symptoms [18]. However, the Interstitial Cystitis Clinical
Trials Group conducted a placebo-controlled trial to evaluate
the efficacy of PPS and hydroxyzine, and found no
statistically significant benefit to treatment with PPS.[19]I n
a systematic review of the pharmacologic management of IC/
PBS by Dimitrakov et al., the pooled estimate of the effect of
pentosan polysulfate therapy suggested a modestbenefit,with
a relative risk of 1.78 for patient-reported improvement in
symptoms (95% confidence interval, 1.34–2.35)[20]. The
long utilization period identified in our database also points
to at least some therapeutic benefit enjoyed by the subjects.
Alternatively, it may be a result of the manufacturer's
recommendations that long-term therapy (greater than 1 year)
may be needed before a clinical effect occurs.
We also found that more patients who were newly
diagnosed with IC/PBS (31%) underwent hydrodistension,
compared to those with a previous diagnosis (11%), and that
the procedurewasnotrepeatedatahighrate.Hydrodistension
has historically been used both for diagnosis and treatment of
IC/PBS; however, after the NIH Interstitial Cystitis Database
study documented that over 60% of patients regarded as
having IC would have been excluded if the NIDDK criteria
were applied[21], the diagnostic value of hydrodistension in
clinical practice has been questioned[22]. The ICDB study
similarly revealed that hydrodistension was utilized more
frequently among those newly diagnosed (48.4%) compared
to those with a previous diagnosis (25.7%)[16]. Our findings
could partly reflect the use of this procedure as a diagnostic
tool more frequently and less so as a therapeutic maneuver. It
is also possible that when used for therapy, it was not
repeated due to poor efficacy.
In our cohort, 26% of the patients had intravesical
instillations; the average number of instillations ranged from
two to six. A variety of Intravesical instillations have been
used to treat IC/PBS, including silver nitrate, marcaine/
lidocaine, dimethyl sulfoxide (DMSO), hyaluronic acid,
heparin, PPS, Bacillus Calmette-Guerin (BCG), and rosin-
iferatoxin. DMSO is the only FDA approved intravesical
agentforthetreatmentofthiscondition.TheavailableIngenix
data do not allow us to identify the exact agent used for the
instillations. These instillations are sometimes given as a 4–
6 week course of therapy, while at other times they are given
as ‘rescue’ therapy for symptom flares. These different uses
may explain the variable numbers of instillations observed in
our dataset.
A summation of all individual incremental care in patients
with IC/PBS, exclusive of indirect costs, is estimated at $100
million in the US alone[5], and medical expenditures among
IC/PBS patients are double the figure associated with those
without the disease[23]. In our cohort, the overall expendi-
tures related to the treatment of IC/PBS were $2,808 per
subject over 5 years, the majority of which were related to
oral medical therapy. PPS, the only FDA approved medica-
tion, was the most expensive at $36 per week. The weekly
cost of $18 for oxybutynin and tolterodine is likely related to
the use of the brand name or extended release formulations,
which are more costly than short-acting formulas.
Although detailed clinical information cannot be obtained
from claims-based data, claims data provides information
about real-world practice patterns, including pharmacy care,
in a large population of individuals. However, this study, like
may claims-based analyses, has limitations. It is also
important to note that this project is not designed to study
the epidemiology of the disease, or to understand the rationale
behind treatment, but rather studies a cohort of patients from
1 year treated by multiple providers. Claims-based data are
designed for billing purposes, and therefore lack important
information about severity of illness and reasons for treatment
discontinuation.Codingisoftenincompleteorinaccurate,and
our cohort may have included some patients with overactive
bladder symptoms or other types of pelvic pain unrelated
to IC/PBS. It is also possible that we excluded some
subjects if their condition was coded using a combination
of ICD-9 codes such as bladder pain and urgency/
Treatment N treated Percentage treated (%) Total cost
All cases Intravesical 23 26 $8,022
Hydrodistension 20 22 $37,676
Incident cases Intravesical 9 17 $3,648
Hydrodistension 16 30 $30,141
Table 4 Utilization and cost of
intravesical treatment and
hydrodistention
398 Int Urogynecol J (2011) 22:395–400frequency, since we identified the cohort by the ICD-9
diagnosis for IC/PBS (595.1). Also, our cohort was older
( m e a na g e6 3 . 3y e a r s )t h a nt h er e p o r t e dm e a na g ef o r
patients with IC/PBS (age range 43–59 years) [2,
19,24,25]. This could be partly due to the population
under study; the population studied consists of the retirees,
employees, and their dependants with a mean and median
age of 58.5 and 59 years, respectively during the study
year of 1999. Thus, our findings may not be entirely
generalizable to a younger IC/PBS population.
Conclusions
The majority of treatment costs for IC/PBS were attribut-
able to oral medical therapy. Anticholinergics, PPS,
tricyclic antidepressants, and gabapentin are the most
commonly used group of such treatments. Subjects likely
tolerated these medications well, as the average length of
treatment exceeded 1 year. Hydrodistension and intravesical
instillations were utilized in less than a quarter of the
patients and not repeated when used. This may be due to its
utilization as part of diagnostic algorithm more frequently
than as a treatment modality.
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Appendix 1
Appendix 2
Table 6 IC treatments and corresponding CPT codes
Treatment Procedure CPT code
Intravesical 51700, 51720
Marcaine J3490
Lidocaine J2000
Heparin J1644
Dimethyl sulfoxide
(DMSO)
J1212
Hyaluronic acid
Chondroitin sulfate 82485
Pentosan
polysulfate
BCG 90586, J9031
Resiniferatoxina
Botox J0585
Cystoscopy
under anesthesia
52000 and 00910
Hydrodistension 52260
Surgical Interstim
(neuromodulation)
64681, 64590, 64555,
64561,64575, 64581
Removal/revision
Interstim
64585, 64595
Cystectomy 51550, 51555, 51565,
51590, 51595, 51596
Augmentation
cystoplasty
51960
Urinary diversion 51596, 51595, 51590
Neobladder 51596
Table 5 List of oral medications queried
Oral medical therapy
Tricyclic antidepressants Elavil (amitriptyline)
Norpramin (desipramine)
Pamelor (nortriptyline)
Sinequan (doxepin)
Tofranil (imipramine)
Antihistamines Vistaril (hydroxyzine pamoate)
Atarax (hydroxyzine hydrochloride)
H2 blockers Tagamet (cimetidine)
Zantac (ranitidine)
Table 5 (continued)
Oral medical therapy
Leukotriene inhibitors Singulair (montelukast)
Accolate (zafirlukast)
Anticonvulsants Neurontin (gabapentin)
Klonopin (clonazepam)
Antispasmotic and analgesic Urimax
Pyridium
Pyridium-plus
Urised
Antispasmotic
andanticholinergic
Ditropan, Ditropan XL (oxybutinin)
Detrol, Detrol LA (tolterodine)
Levsin, Levbid, Levsinex
(hyoscyamine)
Urispas (Flavoxate)
Bentyl (dicyclomine)
Pro-Banthine (propantheline)
Mucosal surface protectants Elmiron
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